CD34+/CD38- acute myelogenous leukemia cells aberrantly express Aurora kinase A

International Journal of Cancer

Volumn 133, Issue 11, 2013, Pages 2706-2719

  Yang, Jing ^a   Ikezoe, Takayuki ^a   Nishioka, Chie ^a   Nobumoto, Atsuya ^a   Udaka, Keiko ^a   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

apoptosis; AURKA; CD34+ CD38 AML cells; MLN8237

Indexed keywords

ALISERTIB; AURORA A KINASE; CD34 ANTIGEN; CD38 ANTIGEN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; AURKA; CD34+/CD38- AML CELLS; MLN8237;

ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; APOPTOSIS; AURORA KINASE A; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MOLECULAR TARGETED THERAPY; PYRIMIDINES;

EID: 84884907647     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28277     Document Type: Article

References (44)

1. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloidleukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
3. Blair A, Sutherland HJ,. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660-71.
4. Blair A, Hogge DE, Sutherland HJ,. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood 1998; 92: 4325-35.
5. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
6. Ikezoe T, Yang J, Nishioka C, et al. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+) /CD38(-) cells and sensitizes them to antileukemia agents. Int J Cancer 2011; 128: 2317-25.
7. Carmena M, Earnshaw WC,. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54.
8. Ikezoe T,. Aurora kinases as an anti-cancer target. Cancer Lett 2008; 262: 1-9.
9. Marumoto T, Zhang D, Saya H,. Aurora kinase A-a guardian of poles. Nat Rev Cancer 2005; 5: 42-50.
10. Tanaka T, Kimura M, Matsunaga K, et al. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59: 2041-4.
11. Ewart-Toland A, Dai Q, Gao YT, et al. Aurora kinase A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005; 26: 1368-73.
12. Yang F, Guo X, Yang G, et al. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod Pathol 2011; 24: 836-45.
13. Jeng YM, Peng SY, Lin CY, et al. Overexpression and amplification of Aurora kinase A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71.
14. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55-62.
15. Liu Q, Kaneko S, Yang L, et al. Aurora kinase A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279: 52175-82.
16. Anand S, Penrhyn-Lowe S, Venkitaraman AR,. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
17. Cammareri P, Scopelliti A, Todaro M, et al. Aurora kinase A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010; 70: 4655-65.
18. Huang XF, Luo SK, Xu J, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora kinase A-high acute myeloid leukemia. Blood 2008; 111: 2854-65.
19. Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of Alisertib (MLN8237), an investigational small molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011; 17: 7614-24.
20. Cervantes-Ruiperez A, Elez ME, Rosello S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective Aurora kinase A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009; 27: 2565 (Meeting Abstract # 2565).
21. Zhang M, Huck J, Hyer M, et al. Effect of Aurora kinase A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol 2009; 27: 8553 (Meeting Abstract # 8553).
22. Görgün G, Calabrese E, Hideshima T, et al. A novel Aurora kinase A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010; 115: 5202-13.
23. Tomita M, Mori N,. Aurora kinase A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 2010; 101: 1204-11.
24. - acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Int J Cancer 2013; 132: 2006-19.
25. Ikezoe T, Tanosaki S, Krug U, et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004; 104: 237-42.
26. Hegde S, Hankey P, Paulson RF,. Self-renewal of leukemia stem cells in friend virus-induced erythroleukemia requires proviral insertional activation of Spi1 and Hedgehog signaling but not mutation of p53. Stem Cells 2012; 30: 121-30.
27. Nishioka C, Ikezoe T, Yang J, et al. Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T-cells via inhibition of the nuclear factor-κB signal pathway. Leukemia 2007; 21: 1044-9.
28. Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 2008; 154: 270-84.
29. Littlepage LE, Wu H, Andresson T, et al. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora kinase A. Proc Natl Acad Sci USA 2002; 99: 15440-5.
30. Satinover DL, Leach CA, Stukenberg PT, et al. Activation of Aurora kinase A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci USA 2004; 101: 8625-30.
31. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110: 2034-40.
32. Kojima K, Konopleva M, Tsao T, et al. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008; 112: 2886-95.
33. Ikezoe T, Yang J, Nishioka C, et al. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int J Hematol 2010; 91: 69-77.
34. Oltvai ZN, Milliman CL, Korsmeyer SJ,. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
35. Ruvolo PP, Deng X, May WS,. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515-22.
36. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125-31.
37. Campbell CJ, Lee JB, Levadoux-Martin M, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010; 116: 1433-42.
38. Xiang Z, Luo H, Payton JE, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest 2010; 120: 2109-18.
39. Hung LY, Tseng JT, Lee YC, et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora kinase A gene expression. Nucleic Acids Res 2008; 36: 4337-51.
40. Kato Y, Iwama A, Tadokoro Y, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 2005; 202: 169-79.
41. Wang Z, Li G, Tse W, et al. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009; 113: 4856-65.
42. Ochi T, Fujiwara H, Suemori K, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113: 66-74.
43. Ikezoe T, Takeuchi T, Yang J, et al. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009; 89: 1364-73.
44. Goldberg SL, Fenaux Pierre, Craig MD, et al. Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood 2010; 116: 3273 (ASH Annual Meeting Abstract #3273).